Business
ABVC BioPharma Gains Confidence From International Investors to Support Growth Path
SILICON VALLEY, CA - August 6, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology...
About this update from Abvc Biopharma, Inc.
[{"type":"image","caption":"","headline":"ABVC BioPharma Highlights Safety Profile of Its Plant-Based ADHD Candidate Amid Growing Concerns About Psychiatric Polypharmacy in the United States","size":{"original":{"width":140,"height":78,"url":"https://media.zenfs.com/en/newsmediawire_165/abacbb2aeeae890aef297a130fea97c7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/X_qKvHxujBtXyrHhszohog--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTExNztjZj13ZWJw/https://media.zenfs.com/en/newsmediawire_165/abacbb2aeeae890aef297a130fea97c7","width":140,"height":78}}},{"type":"text","content":"SILICON VALLEY, CA - August 6, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, is pleased to share that it has received continued investment support from international investors. These investors, after an independent evaluation of the Company's business and operations, made a private investment into the Company's equity; demonstrating belief in the Company's current and future plans.","length":581,"tagName":"p"},{"type":"text","content":"The capital raised through these placements - totaling over USD 2.5 million - provides ABVC near-term operating flexibility and reflects growing confidence in its therapeutic innovations. The structured six-month lock-up period underlines their intent to support the Company through its next milestones.","length":303,"tagName":"p"},{"type":"text","content":""Teams evolve, ideas shift - but what remains constant is the credibility of the product," said Dr. Uttam Patil, ABVC's Chief Executive Officer. "We are building a company grounded in real science and long-term value. Our team is working tirelessly to translate the Company's potential into real success."","length":333,"tagName":"p"},{"type":"text","content":"The support gained from these investments gives ABVC's management and Board validation of the Company's product vision and the team's leadership and strategic execution. With this foundation in place, ABVC is actively pursuing additional partnerships and licensing - to advance its clinical programs and expand shareholder value.","length":341,"tagName":"p"},{"type":"text","content":"About ABVC BioPharma & Its Ind...